Vicore Pharma Holding AB

Vicore Pharma Holding AB has announced the composition of its Nomination Committee for the upcoming 2027 Annual General Meeting (AGM), scheduled for May 5, 2027. The committee comprises representatives from the company's three largest shareholders as of August 31, 2026, along with Vicore's chairman. The committee's responsibilities include preparing proposals for board elections, auditor appointments, and setting rules for the subsequent year's nomination committee. Shareholders have until January 15, 2027, to submit any comments or proposals.

Vicore Pharma Holding AB announced the appointment of Rob Slack, PhD, FRSB, as its new Chief Scientific Officer, effective July 6, 2026. Dr. Slack brings over two decades of leadership in drug discovery, particularly in respiratory biology and fibrosis, having previously held senior roles at GSK and Galecto. He will lead the company's research strategy and pipeline development, succeeding Johan Raud, MD, PhD, who will transition to a Senior Advisor role.